Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 21, Pages 5503
Publisher
MDPI AG
Online
2019-11-05
DOI
10.3390/ijms20215503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-κB in B-cell lymphomas to increase MIP-1α production
- (2019) Ryan Incrocci et al. JOURNAL OF MEDICAL VIROLOGY
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatty acid transport protein 2 reprograms neutrophils in cancer
- (2019) Filippo Veglia et al. NATURE
- Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors
- (2019) Andrea Ponzetta et al. CELL
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment
- (2018) Fathima Zumla Cader et al. BLOOD
- Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
- (2018) Anja Mottok et al. BLOOD
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
- (2018) Valeria Spina et al. BLOOD
- Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
- (2018) Tycel J. Phillips et al. BLOOD
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
- (2018) Eleni Anastasiadou et al. LEUKEMIA
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype
- (2018) Bastian Dörsam et al. Frontiers in Immunology
- Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
- (2018) Jodi Chiu et al. Frontiers in Immunology
- Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study
- (2018) Paolo Strati et al. HAEMATOLOGICA
- Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
- (2018) Silvia L. Locatelli et al. CLINICAL CANCER RESEARCH
- Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
- (2017) Peter Borchmann et al. LANCET ONCOLOGY
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-κB Activation and Cell Survival
- (2017) Sebastian Horn et al. Cell Reports
- Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma
- (2017) Frederik Wein et al. Cancer Immunology Research
- Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution
- (2016) S. S. Kenderian et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance
- (2016) Donatella Aldinucci et al. CANCER LETTERS
- The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
- (2016) Annika Englund et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients
- (2016) Raffaella Marcheselli et al. HEMATOLOGICAL ONCOLOGY
- Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma
- (2016) Manuel Gotti et al. HEMATOLOGICAL ONCOLOGY
- The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis
- (2016) Antonino Carbone et al. INTERNATIONAL JOURNAL OF CANCER
- Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study
- (2016) Armando Santoro et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Erratum: Corrigendum: PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma
- (2016) Wei Ju et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- How neutrophils promote metastasis
- (2016) T. Tuting et al. SCIENCE
- Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients
- (2016) Olivia Marini et al. Oncotarget
- Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
- (2015) Thomas Condamine et al. Annual Review of Medicine
- Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome
- (2015) Maja D. Andersen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment
- (2015) Emanuele Cencini et al. HEMATOLOGICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of T cells in the microenvironment of Hodgkin lymphoma
- (2015) Frederik Wein et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment
- (2015) Antonino Carbone et al. JOURNAL OF PATHOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
- (2015) John E. Janik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
- (2015) Jitka Y. Sagiv et al. Cell Reports
- CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma
- (2014) Jonathan L. Klein et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2014) J.-I. Youn et al. JOURNAL OF IMMUNOLOGY
- The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing
- (2014) Y Liu et al. LEUKEMIA
- Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma
- (2014) Christiane Silke Tudor et al. PLoS One
- IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
- (2014) Francesco Di Raimondo et al. Mediterranean Journal of Hematology and Infectious Diseases
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
- (2013) J. A. Kanakry et al. BLOOD
- Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
- (2013) P. Greaves et al. BLOOD
- Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma
- (2013) J. Ouyang et al. BLOOD
- Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma
- (2013) Graham P. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Tumor associated macrophages and neutrophils in cancer
- (2013) Maria Rosaria Galdiero et al. IMMUNOBIOLOGY
- Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
- (2013) Boris Böll et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
- (2013) Carla Casulo et al. LEUKEMIA RESEARCH
- Prognostic Significance of the Ratio of Absolute Neutrophil Count to Absolute Lymphocyte Count in Classic Hodgkin Lymphoma
- (2012) Young Wha Koh et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
- (2012) A. Younes et al. BLOOD
- Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
- (2012) Claudia A. Dumitru et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome
- (2012) Paul Greaves et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
- (2011) D. Azambuja et al. ANNALS OF ONCOLOGY
- JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
- (2011) K. Van Roosbroeck et al. BLOOD
- PI3K inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
- (2011) S. A. Meadows et al. BLOOD
- Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
- (2011) P. Kamper et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin’s Lymphoma - a population-based study
- (2011) Ingrid Glimelius et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
- (2011) Christian Steidl et al. JOURNAL OF CLINICAL ONCOLOGY
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
- (2010) M. Sant et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Myeloid-derived suppressor cell heterogeneity and subset definition
- (2010) Elisa Peranzoni et al. CURRENT OPINION IN IMMUNOLOGY
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth
- (2010) A McGarry Houghton et al. NATURE MEDICINE
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
- (2009) G. Dancey et al. CLINICAL CANCER RESEARCH
- IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
- (2009) Susanna Mandruzzato et al. JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization
- (2008) S. Hartmann et al. HAEMATOLOGICA
- Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
- (2008) Sabine Schreck et al. HEMATOLOGICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search